HENGRUI PHARMA - Jiangsu Hengrui Pharmaceutical Co., Ltd.’s Progress Announcement on Repurchasing Company Shares A

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company")

The Shanghai Stock Exchange website (www.sse.com.cn) published the following announcement. They are listed below for reference only.

By order of the board of directors Jiangsu Hengrui Pharmaceutical Co., Ltd. Chairman

Mr. Sun Piaoyang

Shanghai, China August 4, 2026

As at the date of this announcement, the members of the Board of Directors include (i) Executive Directors Mr. Sun Piaoyang, Mr. Dai Hongbin, Mr. Feng Jinu; Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) Ms. Guo Congzhao, a non-executive director; and (iii)

Independent non-executive directors Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.

Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-112

Jiangsu Suhengheng Rui Medical Pharmaceutical Co., Ltd.

Announcement on the progress of the repurchase of the company's shares A

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

statements or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its contents.

Important content reminder:

The first disclosure date of the repurchase plan is 2025/8/21 The implementation period of the buyback plan is August 20, 2025 ~ August 19, 2026 Estimated repurchase amount: 1 million yuan to 2 million yuan

□Reduce registered capital √Used for employee stock ownership plans or equity incentives Repurchase purpose □Used to convert company convertible bonds □To protect the company’s value and shareholders’ rights and interests The cumulative number of shares repurchased is 13.7502 million shares The cumulative number of shares repurchased accounts for 0.21% of the total share capital. The cumulative repurchased amount is 853.0848 million yuan Actual repurchase price range: 45.30 yuan/share~70.00/yuan/share

11. Basic information on the repurchase of shares Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held its first meeting on August 20, 2025

The 18th meeting of the 9th Board of Directors reviewed and approved the "Repurchase of the Company's A Shares through Centralized Bidding Transactions"

"Proposal on the Plan", agreeing that the company will use its own funds to repurchase the company's shares through centralized bidding transactions for

Implement the A-share employee stock ownership plan. The repurchase price does not exceed RMB 90.85 per share (inclusive), and the total repurchase funds

Not less than RMB 1 billion and not more than RMB 2 billion. The repurchase period is from the time when the board of directors approves the repurchase of shares. Within 12 months from the date of the plan. For details, please see the company’s disclosure on the Shanghai Stock Exchange website

"Repurchase Report on the Repurchase of the Company's A Shares through Centralized Bidding" (www.sse.com.cn)

Book" (Announcement No.: Pro 2025-130).

22. Progress of the repurchase of shares

According to the "Share Repurchase Rules of Listed Companies" and "Self-Regulatory Supervision Guidelines for Listed Companies of the Shanghai Stock Exchange" No. 7 No. - Repurchase of Shares", the progress of the company's share repurchase is now announced as follows:

In July 2026, the company repurchased shares through centralized bidding transactions through the Shanghai Stock Exchange trading system.

280,000 shares, the shares repurchased accounted for 0.004% of the company’s total share capital, and the highest purchase price was RMB

54.05 yuan/share, the lowest price is RMB 53.75/share, and the total amount paid is RMB 1,508.88 Ten thousand yuan (excluding transaction fees).

As of July 31, 2026, the company’s share repurchase plan has accumulated through the Shanghai Stock Exchange.

Yi Systems repurchased 13.7502 million shares through centralized bidding transactions, and the repurchased shares accounted for 10% of the company's total share capital.

The ratio is 0.21%. The highest purchase price is RMB 70.00 per share and the lowest price is RMB 45.30 per share.

shares, the total amount paid was RMB 853.0848 million (excluding transaction fees). The above-mentioned repurchase complies with the provisions of relevant laws and regulations and the company's established share repurchase plan.

33. Other matters

The company will strictly follow the "Share Repurchase Rules of Listed Companies" and the "Self-Discipline Supervision of Listed Companies of the Shanghai Stock Exchange".

According to relevant regulations such as Management Guideline No. 7 - Repurchase of Shares, decisions should be made based on market conditions during the repurchase period.

Repurchase decisions will be made and implemented, and at the same time, information disclosure obligations will be performed in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.

Announcement is hereby made.

Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.

August 4, 2026